| 合资、国产恩替卡韦治疗慢性乙型肝炎的最小成本分析 |
| 投稿时间：2012-11-17 修订日期：2013-05-09 点此下载全文 |
| 引用本文：邬亚妙.合资、国产恩替卡韦治疗慢性乙型肝炎的最小成本分析[J].药学实践杂志,2013,31(5):388~389 |
| 摘要点击次数: 1073 |
| 全文下载次数: 375 |
|
|
| 中文摘要:目的 探讨合资、国产恩替卡韦治疗慢性乙型肝炎的有效性及经济性。方法 回顾性分析本院专家门诊2009年10月~2010年10月治疗的慢性乙型肝炎患者65例, A组33例,给予合资恩替卡韦,0.5 mg,口服1次/d;B组32例,给予国产恩替卡韦,0.5 mg,口服1次/d。治疗48周观察疗效,并采用最小成本法分析。结果 在ALT复常率、HBV-DNA转阴率和HBeAg血清转换率等效果方面,两组差异无显著性意义(P＞0.05),A组成本为12 028.8元;B组成本为7 996.8元。结论 国产恩替卡韦治疗慢性乙型肝炎的最小成本优于合资恩替卡韦。 |
| 中文关键词:慢性乙型肝炎 合资 国产 恩替卡韦 最小成本分析 |
| |
| Cost-minimization analysis of joint venture entecavier and domestic entecavier in treating patients with chronic hepatitis B |
|
|
| Abstract:Objective To study the validity and affordability between joint venture entercavier and domestic entercavier in treating patients with chronic hepatitis B.Methods 65 patients with chronic hepatitis B were select who were treated with entercavier between Oct. 2009 to Oct.2010 in Ningbo No. 2 Hospital expert outpatient service. These patients were divide into group A (33 cases) and B(32 cases). Group A was treated with joint venture entecavier and group B was treated with domestic ones. all patients were given 0.5 mg daily and treated for 48 weeks. The cost-minimization analysis was made between two groups.Results ALT recovery rate, HBV-DNA negative conversion rate and HBeAg serum conversion rate had no statistically significant between two groups (P>0.05), but the cost of group A was 12 028.8, and the cost of group B was 7 996.8.Conclusions The domestic entecavier was better than the joint venture entecavier in treating the patients with chronic hepatitis B by cost-minimization analysis. |
| keywords:chronic hepatitis B joint venture domestic entecavier cost-minimization analysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
